- Home
- YMAT vs IMMX Comparison
YMAT vs IMMX Comparison
Compare YMAT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAT
- IMMX
- Stock Information
- Founded
- YMAT 1970
- IMMX 2014
- Country
- YMAT Taiwan
- IMMX United States
- Employees
- YMAT N/A
- IMMX N/A
- Industry
- YMAT Recreational Games/Products/Toys
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- YMAT Consumer Discretionary
- IMMX Health Care
- Exchange
- YMAT Nasdaq
- IMMX Nasdaq
- Market Cap
- YMAT 76.4M
- IMMX 65.5M
- IPO Year
- YMAT 2025
- IMMX 2021
- Fundamental
- Price
- YMAT $5.59
- IMMX $2.19
- Analyst Decision
- YMAT
- IMMX Strong Buy
- Analyst Count
- YMAT 0
- IMMX 1
- Target Price
- YMAT N/A
- IMMX $7.00
- AVG Volume (30 Days)
- YMAT 808.5K
- IMMX 255.8K
- Earning Date
- YMAT 01-01-0001
- IMMX 08-08-2025
- Dividend Yield
- YMAT N/A
- IMMX N/A
- EPS Growth
- YMAT N/A
- IMMX N/A
- EPS
- YMAT 0.07
- IMMX N/A
- Revenue
- YMAT $17,563,985.00
- IMMX N/A
- Revenue This Year
- YMAT N/A
- IMMX N/A
- Revenue Next Year
- YMAT N/A
- IMMX N/A
- P/E Ratio
- YMAT $79.80
- IMMX N/A
- Revenue Growth
- YMAT N/A
- IMMX N/A
- 52 Week Low
- YMAT $3.80
- IMMX $1.26
- 52 Week High
- YMAT $6.45
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- YMAT N/A
- IMMX 39.38
- Support Level
- YMAT N/A
- IMMX $2.11
- Resistance Level
- YMAT N/A
- IMMX $2.39
- Average True Range (ATR)
- YMAT 0.00
- IMMX 0.21
- MACD
- YMAT 0.00
- IMMX -0.03
- Stochastic Oscillator
- YMAT 0.00
- IMMX 9.52
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.